FibroGen CEO Enrique Conterno Steps Down Amidst Challenges and Setbacks
-
Drug News
FibroGen CEO Enrique Conterno Steps Down Amidst Challenges and Setbacks
In early 2020, FibroGen’s expectations were high for the anemia drug roxadustat when Enrique Conterno became the company’s new CEO.…
Read More »
